Contents
pdf Download PDF
pdf Download XML
331 Views
31 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 441 - 447
Comparative Assessment of FIB-4 Index and APRI Score for Identifying Advanced Liver Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes Mellitus
 ,
 ,
 ,
 ,
 ,
1
Consultant Gastroenterologist, Department of Gastroenterology, Bahawal Victoria Hospital, Bahawalpur, Pakistan
2
FCPS, Postgraduate Resident, Internal Medicine, Chiniot General Hospital Korangi, Karachi, Pakistan
3
Assistant Professor of Gastroenterology, Department of Medicine and Allied, Jinnah Medical and Dental College, Karachi, Pakistan
4
Senior Registrar, Gastroenterology, Shahida Islam Medical and Dental College, Lodhran, Pakistan
5
Senior Assistant Professor, Physiology, Bahria University Health Sciences Campus, Karachi, Pakistan
6
Associate Professor, Gastroenterology, Department of Medicine, Gajju Khan Medical College, Swabi, Pakistan
Under a Creative Commons license
Open Access
Received
Aug. 14, 2026
Revised
Oct. 27, 2026
Accepted
Nov. 8, 2026
Published
Nov. 20, 2026
Abstract

Advanced liver fibrosis is a common complication of metabolic dysfunction-associated steatotic liver disease (MASLD) that is also associated with type 2 diabetes mellitus (T2DM). Non-invasive diagnostic indices may aid in early identification of high-risk patients. Objective: To compare the diagnostic performance of the FIB-4 index and APRI score for identifying advanced liver fibrosis in patients with MASLD and T2DM. Methods: This was an analytical cross-sectional study conducted at Bahawal Victoria Hospital, Bahawalpur, from November 1st, 2025, to April 30, 2026. Consecutive sampling was used to recruit 120 patients. Demographic, clinical, and biochemical parameters were noted. Advanced fibrosis was evaluated using transient elastography (TE) (>12 kPa), whereas FIB-4 and APRI scores were computed. The diagnostic performance was assessed by sensitivity, specificity, predictive values, accuracy, and area under the receiver operating characteristic curve (AUROC). Results: Advanced fibrosis was identified in 28 (23.3%) patients. FIB-4 demonstrated higher sensitivity (85.7%), specificity (68.5%), and diagnostic accuracy (72.5%) than APRI (78.6%, 57.6%, and 62.5%, respectively). The AUROC was 0.81 (95% CI: 0.72–0.90) for FIB-4 and 0.70 (95% CI: 0.60–0.80) for APRI. Results: FIB-4 had a relatively strong diagnostic ability in detecting advanced liver fibrosis in MASLD patients with T2DM.

Keywords
INTRODUCTION

Metabolic dysfunction-associated steatotic liver disease is now recognized as a significant public health problem because of its link to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), as well as its rising prevalence worldwide.[1] The disease is a spectrum that includes simple steatosis, metabolic dysfunction-associated steatohepatitis (MASH), progression to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).[2] Recent epidemiological data suggest that about 30% of the adult world's population is affected by fatty liver disease and significantly more so in those with metabolic disorders.[3] The overall prevalence of MASLD in patients with T2DM

 

exceeded 65.33% based on the results of a comprehensive meta-analysis of over 2.2 million patients with T2DM.[4] A comprehensive meta-analysis of over 2.2 million patients with T2DM yielded a pooled prevalence of MASLD of 65.33%, showing the high burden of hepatic complications in this high-risk patient population.[5]

 

The presence of MASLD along with T2DM is especially alarming, as this combination promotes hepatic fibrogenesis and the risk of advanced liver disease.[6] Advanced fibrosis is a powerful predictor of liver-related outcomes such as hepatic decompensation, HCC, and death.[7] The systematic review, which included 1,832,125 patients with T2DM, found that 14.95% of patients with NAFLD had advanced fibrosis.[8] Additionally, Wongtrakul et al. (2024) calculated the prevalence of advanced fibrosis to be 19.5% in T2DM patients and 23.5% in those with concomitant MASLD.[9] These results highlight that detection of advanced fibrosis must be done before the onset of irreversible liver damage and clinically relevant complications.

 

Liver biopsy is an important reference method for evaluating hepatic fibrosis but is too invasive, can be complicated, is not always feasible, and is not commonly used for routine screening; thus, this has led to a preference for the use of non-invasive fibrosis assessment markers.[10] Among these, the fibrosis-4 (FIB-4) index and aspartate aminotransferase-to-platelet ratio index (APRI) are widely accessible, inexpensive, and easily calculated using routinely available clinical and laboratory parameters.[11] The FIB-4 index includes age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count, while APRI is based on AST relative to the upper limit of normal and platelet count.[12] The receiver operating characteristic curve (AUROC) for FIB-4 and APRI in determining advanced fibrosis was 0.81 and 0.78, respectively, in a meta-analysis of over 40,000 people with MASLD.[13]

 

FIB-4 is recommended as a first-line risk stratification tool by the current guidelines in Europe, and liver stiffness measurement is recommended.[14]

 

Advanced hepatic fibrosis is an important stage to identify and intervene at to prevent further fibrosis progression and achieve better long-term outcomes in patients with MASLD and T2DM. These factors, however, pose a significant challenge in clinical practice as a result of the heavy burden of metabolic liver disease, the lack of routine use of advanced diagnostic tests, and the performance variability of the available non-invasive scores. While the use of FIB-4 is increasingly being recommended at the initial stage of fibrosis risk assessment, there is still a clinical need to see if FIB-4 is a significant diagnostic benefit when compared with the more basic APRI score in this high-risk population, especially in low-resource healthcare settings. Comparing these easily available indices may be useful to determine a practical, affordable, and reliable method for targeting patients for additional evaluation. The purpose of the current study is to assess the diagnostic utility of the FIB-4 index and APRI score for advanced liver fibrosis in patients with T2DM and MASLD, specifically in terms of their sensitivity, specificity, predictive values, and diagnostic accuracy.

MATERIALS AND METHODS

This hospital-based, analytical cross-sectional study was conducted in the Department of Gastroenterology at Bahawal Victoria Hospital, Bahawalpur, Pakistan. This study was carried out during six months, starting from November 1, 2025, to April 30, 2026.

 

A sample size was determined using the OpenEpi online sample size calculator (Version 3.01) with the single population proportion formula. The expected prevalence of advanced liver fibrosis in patients with coexisting MASLD and type 2 diabetes mellitus was assumed to be 23.5% from the systematic review and meta-analysis performed by Wongtrakul et al. (2024).[9] A 95% confidence level, a margin of error of 8%, and a design effect of 1 were taken into consideration. A sample size of 108 patients was determined as the minimum number needed. The final sample size of 120 patients was calculated after accounting for an expected 10% of incomplete or non-evaluable data.

A consecutive sampling technique was employed, a non-probability sampling technique. Patients attending during the study period who met the criteria for MASLD were screened for T2DM eligibility, and patients who met the inclusion criteria were recruited until the desired number of patients was obtained.

 

The study included patients aged 18 years or older without gender restriction, and those who had been diagnosed with T2DM and/or MASLD. Type 2 diabetes mellitus was diagnosed by medical history, antidiabetic therapy, or previously established diagnostic criteria. The presence of hepatic steatosis on abdominal ultrasonography or transient elastography, with the presence of cardiometabolic dysfunction, was considered evidence of MASLD. Patients who were included had laboratory investigations available that included serum AST, ALT, and platelet count, and a valid liver stiffness measurement for liver fibrosis assessment.

 

Patients who had chronic hepatitis B or C infection, autoimmune hepatitis, Wilson's disease, hemochromatosis, and other chronic liver diseases (excluding MASLD) were excluded. Alcohol consumption higher than levels that would be compatible with the diagnosis of MASLD, current hepatotoxic medications, acute hepatitis, acute systemic infections, and conditions that could have a significant impact on liver enzyme levels or platelet counts were also excluded. The following groups were not included: patients with a history of known hematological disorders that could affect platelet count, history of liver transplantation, and inadequate laboratory data. Patients whose transient elastography was technically invalid and unreliable were excluded from the final diagnostic accuracy analysis.

 

A structured proforma was used to collect data, which had been designed to meet the objectives of this study. All patients were included in the study after signing informed consent. Demographic data (age, gender, weight, height, body mass index (BMI) were obtained. Clinical data on duration of diabetes, antidiabetic medication, hypertension, dyslipidemia, and other related comorbidities were collected by patient interview and medical records. Blood samples were taken for measurements of serum AST, ALT, platelet count, fasting blood glucose, and glycated hemoglobin (HbA1c).

 

The FIB-4 index was determined. The calculated scores were entered for each of the patients, and patients were classified based on the known fibrosis risk thresholds. FIB-4 was classified as low, intermediate, and high risk if below <1.30, between 1.30 and 2.67, and above 2.67, respectively. Patients 65 years old or older were age-adjusted. APRI values of 0.5 and 1.5 were considered conventional thresholds for fibrosis risk stratification.

 

Liver fibrosis was measured by vibration-controlled transient elastography (FibroScan), and liver stiffness was measured in kilopascals (kPa). Standardized procedures and trained personnel were used for the examination. At least 10 technically reliable measurements were taken with an interquartile range-to-median ratio that was acceptable. For the primary analysis, a liver stiffness result of 12 kPa or higher was considered to be suggestive of advanced fibrosis (AF), and a liver stiffness result <12 kPa was considered not to meet the threshold for AF. This classification was used as a ‘working’ definition instead of a histological diagnosis for fibrosis stage F3–F4. A comparison of the diagnostic performances of FIB-4 and APRI was then carried out with the results of transient elastography. All clinical, biochemical and elastography results were recorded on the study proforma and verified for completeness prior to analysis.

 

The data collected was entered and analyzed on IBM SPSS Statistics, version 26.0. Quantitative variables such as age, BMI, duration of diabetes, serum AST, ALT, platelet count, HbA1c, liver stiffness measurements, FIB-4 index and APRI score were presented as mean ± SD or median with interquartile range as appropriate. The categorical variables were presented as frequencies and percentages, such as gender, hypertension, dyslipidaemia, fibrosis risk categories, and advanced fibrosis status. The Shapiro–Wilk test was used to assess the normality of quantitative variables. Independent-samples t-test, chi-square test, and Fisher's exact test for categorical variables were used to compare groups of patients with and without fibrosis at the advanced stage, as appropriate. The sensitivity, specificity, positive predictive value, negative predictive value, and overall diagnostic accuracy of FIB-4 and APRI were evaluated. Two receiver operating characteristic (ROC) curves were plotted, and the area under the ROC curves (AUROC) with 95% confidence intervals were computed for each of the two indices. DeLong's test for correlated ROC curves was used for comparing the AUROCs. A p-value of less than 0.05 was used as the criterion of statistical significance.

RESULTS

In total, 120 patients with MASLD and T2DM were analyzed. Demographic and clinical features revealed a higher proportion of female individuals, and overweight and obesity, hypertension, and dyslipidemia were seen as common conditions among the study population (Table 1).

 

Biochemical parameters were significantly higher in patients with advanced fibrosis compared to patients without. Patients with advanced fibrosis had significantly higher AST, ALT, FBG, HbA1c, and fibrosis indices (FIB-4 and APRI). In contrast, the platelet count was significantly decreased in this group. There were no differences between groups that were not statistically significant (p>0.05) (Table 2). Advanced liver fibrosis was detected by transient elastography in 23.3% of the study population. Table 3 shows patients' distribution by FIB-4 and APRI level in each of the three risk groups. FIB-4 and APRI classification status were both significantly related to advanced fibrosis. FIB-4, however, showed fewer false-positive and false-negative classifications than APRI, and it was more consistent with the results of transient elastography in the study population (Table 4).

 

Comparative analysis of the two diagnostic tests showed that the sensitivity, specificity, predictive value, and overall diagnostic accuracy of FIB-4 were significantly better than those of APRI. These results showed that FIB-4 had a relatively good diagnostic performance at the predefined cutpoints (Table 5). ROC curve analysis also revealed better discriminatory ability of FIB-4 than APRI, as evidenced by a higher AUROC. The difference between the two AUROCs, however, was still not statistically significant (Table 6 and Figure 1).

Figure 1. Receiver operating characteristic (ROC) curves comparing the diagnostic performance of FIB-4 index and APRI score for identifying advanced liver fibrosis in patients with MASLD and T2DM.

 

RESULTS

 

Table 1. Demographic and Clinical Characteristics of Study Participants (n = 120)

Variable

Category / Measurement

Value

Age (years)

Mean ± SD

52.8 ± 10.7

Gender

Male

54 (45.0%)

 

Female

66 (55.0%)

Weight (kg)

Mean ± SD

79.6 ± 13.4

Height (cm)

Mean ± SD

163.4 ± 8.6

BMI (kg/m²)

Mean ± SD

29.8 ± 4.5

Duration of T2DM (years)

Mean ± SD

8.4 ± 5.2

Hypertension

Yes

66 (55.0%)

 

No

54 (45.0%)

Dyslipidemia

Yes

59 (49.2%)

 

No

61 (50.8%)

Antidiabetic treatment

Oral medication only

69 (57.5%)

 

Insulin only

17 (14.2%)

 

Oral medication + insulin

34 (28.3%)

 

Table 2. Comparison of Biochemical Parameters and Non-Invasive Fibrosis Scores According to Advanced Fibrosis Status

Parameter

Without advanced fibrosis (n = 92)

With advanced fibrosis (n = 28)

p-value

AST (U/L)

38.2 ± 14.6

61.3 ± 24.1

<0.001

ALT (U/L)

46.7 ± 19.8

60.0 ± 27.0

0.021

Platelet count (×10⁹/L)

243.6 ± 58.4

161.7 ± 61.3

<0.001

Fasting blood glucose (mg/dL)

161.7 ± 45.3

190.4 ± 57.8

0.021

HbA1c (%)

8.1 ± 1.5

9.4 ± 1.9

0.002

Liver stiffness (kPa)

7.2 ± 2.4

17.5 ± 4.6

<0.001

FIB-4 index

1.31 ± 0.71

3.07 ± 0.93

<0.001

APRI score

0.63 ± 0.35

1.32 ± 0.65

<0.001

 

Table 3. Distribution of Advanced Liver Fibrosis and Fibrosis Risk Categories (n = 120)

Assessment

Category

n (%)

Transient elastography

Without advanced fibrosis (<12 kPa)

92 (76.7%)

 

Advanced fibrosis (≥12 kPa)

28 (23.3%)

FIB-4 index

Low risk (<1.30)

67 (55.8%)

 

Intermediate risk (1.30–2.67)

38 (31.7%)

 

High risk (>2.67)

15 (12.5%)

APRI score

Low risk (<0.50)

59 (49.2%)

 

Intermediate risk (0.50–1.50)

42 (35.0%)

 

High risk (>1.50)

19 (15.8%)

 

Table 4. Comparison of FIB-4 and APRI Classification Against Transient Elastography Findings

Diagnostic assessment

Advanced fibrosis

(n = 28), n (%)

Without advanced fibrosis

(n = 92), n (%)

p-value

FIB-4 positive (≥1.30)

24 (85.7%)

29 (31.5%)

<0.001

FIB-4 negative (<1.30)

4 (14.3%)

63 (68.5%)

 

APRI positive (≥0.50)

22 (78.6%)

39 (42.4%)

<0.001

APRI negative (<0.50)

6 (21.4%)

53 (57.6%)

 

 

Table 5. Comparative Diagnostic Performance of FIB-4 and APRI for Identifying Advanced Liver Fibrosis

Diagnostic parameter

FIB-4 (≥1.30)

APRI (≥0.50)

True positives (TP)

24

22

False positives (FP)

29

39

True negatives (TN)

63

53

False negatives (FN)

4

6

Sensitivity (%)

85.7

78.6

Specificity (%)

68.5

57.6

Positive predictive value (%)

45.3

36.1

Negative predictive value (%)

94.0

89.8

Overall accuracy (%)

72.5

62.5

 

Table 6. Receiver Operating Characteristic (ROC) Curve Analysis of FIB-4 and APRI

Parameter

FIB-4 index

APRI score

AUROC

0.81

0.70

95% confidence interval

0.72–0.90

0.60–0.80

Difference in AUROC

0.11

Reference

Diagnostic discrimination

Good

Fair

 

DISCUSSION

In the study, 23.3% of the patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) had a liver fibrosis stage of ≥2 on transient elastography. Patients with advanced fibrosis had higher AST, HbA1c, FIB-4, and APRI levels and lower platelet counts. Overall, the results were consistent with the results of a 2023 study of T2DM patients with metabolic dysfunction-associated fatty liver disease, which found that 10% had advanced fibrosis and significant relationships between fibrosis and metabolic parameters.[15] Also, a 2025 study from the eastern part of India focused on the role of non-invasive assessment in diabetic patients with NAFLD, highlighting the need for it in this patient group. Variations in prevalence reported may be due to patient selection and/or different definitions of fibrosis.[16]

 

Results of the diagnostic analysis showed that FIB-4 performed better than APRI, with 85.7% and 78.6% sensitivity, respectively. This was consistent with Noureen et al. (2025), who reported an AUROC of 0.86 for FIB-4 in patients with NAFLD and NASH.[17] Likewise, López Tórrez et al. (2024), in their meta-analysis of more than 40,000 individuals, found AUROC scores of 0.81 and 0.78 for FIB-4 and APRI, respectively, for the prediction of advanced fibrosis.[13] These results indicated that FIB-4 could have a role in initial fibrosis assessment, with variable diagnostic performance depending on the population.[13]

 

A 2021 Iranian study, however, found that APRI was better than FIB-4 to differentiate advanced fibrosis, with a reported accuracy of 87.3% for APRI and 78.0% for FIB-4.[18] Similarly, a study conducted in Bangladesh in 2025 found that APRI (AUROC 0.76) had a slightly higher level of discrimination than FIB-4 (AUROC 0.73) among patients with NAFLD and T2DM.[19] Huang et al. (2024) also showed differences in the effectiveness of these indices by liver disease etiology.[20] The results of these comparisons showed that neither score had consistent superiority across all clinical settings.

The ROC analysis showed AUROC values of 0.81 for FIB-4 and 0.70 for APRI. Similar findings were reported by Roy et al (2026), who found stronger diagnostic discrimination of FIB-4 compared to APRI for MASLD.[21] The results of a Japanese multicenter study published in 2026 were similar, with AUROC values of 0.719 for FIB-4 and 0.665 for APRI.[22] Moreover, Yi et al. 2025, found that both measurements had different diagnostic performance based on the different etiologies of FLD among patients with T2DM.[23] These studies indicated that patient characteristics and underlying disease patterns should be taken into account when interpreting fibrosis scores.

 

Overall, the results indicated that FIB-4 could provide improved discrimination compared to the APRI for advanced fibrosis in T2DM patients with MASLD. The single-center, the small sample size, the non-probability sampling, and the use of transient elastography instead of liver biopsy would, however, limit the interpretation and generalizability of the findings. In addition, the difference between the two AUROCs was not statistically significant.

Overall, the results indicated that FIB-4 may provide greater discrimination than APRI in the identification of advanced fibrosis in patients with MASLD and T2DM. The interpretation of the results and generalizability of the findings would be, however, limited by the proposed single-center design and relatively small number of patients, and by the fact that these patients were not sampled from a population-based cohort, but were assessed by transient elastography rather than liver biopsy. Moreover, it was not determined whether there was a significant difference between the two AUROCs. Further large multicenter studies would be needed to establish whether FIB-4 has a valuable diagnostic benefit over APRI in this population.

 

LIMITATIONS

The following were some of the limitations of the proposed study. The study's findings might not be generalizable because it was limited in scope and design, with only 120 patients. The non-probability consecutive sampling technique might have introduced selection bias. Transient elastography was used to assess for advanced fibrosis; this may have led to misclassification if liver biopsy had been performed. In addition, as the design was cross-sectional, the progression of fibrosis was not assessed over time. The diagnostic performance of FIB-4 and APRI may also have been affected by factors related to age, metabolic disturbances, or inter-individual differences in liver enzyme levels.

CONCLUSION

The findings suggested that the FIB-4 index demonstrated better diagnostic performance than APRI for identifying advanced liver fibrosis among patients with MASLD and T2DM. FIB-4 showed higher sensitivity, specificity, and overall diagnostic accuracy, indicating its potential usefulness as an initial non-invasive screening tool. The difference in diagnostic performance between the two indices, however, needed to be further statistically supported, and neither could replace confirmatory fibrosis assessment. Larger multicenter studies were recommended to establish their clinical utility.

REFERENCES
  1. Younossi, Z.M., M. Kalligeros, and L. Henry, Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clinical and molecular hepatology, 2024. 31(Suppl): p. S32.
  2. Huang, D.Q., et al., Metabolic dysfunction-associated steatotic liver disease in adults. Nature Reviews Disease Primers, 2025. 11(1): p. 14.
  3. Henry, L., J. Paik, and Z.M. Younossi, the epidemiologic burden of non‐alcoholic fatty liver disease across the world. Alimentary pharmacology & therapeutics, 2022. 56(6): p. 942-956.
  4. Ştefan, A.G., et al., MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review. Medicina, 2026. 62(2): p. 325.
  5. Singhai, A., et al., Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis. The Indian Journal of Medical Research, 2026. 164(1): p. 72.
  6. Cusi, K., et al., Metabolic dysfunction–associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care, 2025. 48(7): p. 1057-1082.
  7. Pearson, M., et al., Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality. JHEP Reports, 2024. 6(6): p. 101062.
  8. Ding, Y., et al., Clinical classification of obesity and implications for metabolic dysfunction-associated fatty liver disease and treatment. Diabetes, Metabolic Syndrome and Obesity, 2023: p. 3303-3329.
  9. Wongtrakul, W., et al., Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology, 2024. 39(11): p. 2299-2307.
  10. Heyens, L.J., et al., Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Frontiers in medicine, 2021. 8: p. 615978.
  11. Salehi, A.M., et al., Can Noninvasive Tests Reduce the Need for Liver Biopsy? A Cross‐Sectional Diagnostic Accuracy Study Assessing NFS, FIB‐4, APRI, BARD, BAAT, API, and AAR for Advanced Fibrosis in MASLD Patients in Iran. International Journal of Clinical Practice, 2026. 2026(1): p. 6674792.
  12. Moosavy, S.H., et al., AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran. BMC gastroenterology, 2023. 23(1): p. 145.
  13. López Tórrez, S.M., et al., Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants. Frontiers in nutrition, 2024. 11: p. 1284509.
  14. Graupera, I., et al., Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clinical Gastroenterology and Hepatology, 2022. 20(11): p. 2567-2576. e6.
  15. Sanchez-Bao, A.M., et al., Identifying advanced MAFLD in a cohort of T2DM and clinical features. Frontiers in endocrinology, 2023. 14: p. 1058995.
  16. Sanyal, D., et al., Prevalence of Hepatic Fibrosis and Performance of Non-invasive Liver Fibrosis Scores in an Eastern Indian Diabetic Population with NAFLD. J ASEAN Fed Endocr Soc, 2025. 40(2): p. 56-64.
  17. Noureen, S., et al., Comparative Efficiency of APRI vs. FIB-4 in Detecting Advanced Liver Fibrosis in NAFLD and NASH. Biological and Clinical Sciences Research Journal, 2025. 6(6): p. 394-397.
  18. Amernia, B., et al., FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterology, 2021. 21(1): p. 453.
  19. Alam, M.S., et al., Comparison of FIB-4, APRI and AST/ALT ratio with FibroScan in patients with NAFLD and type 2 diabetes: a single-center study from Bangladesh. Egyptian Liver Journal, 2025. 15(1): p. 38.
  20. Huang, C.F., et al., Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis. The Kaohsiung Journal of Medical Sciences, 2024. 40(4): p. 374-383.
  21. Roy, A., et al., Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis. BMC Gastroenterology, 2026. 26(1): p. 329.
  22. Morishita, A., et al., Sequential Fibrosis-4 Index and Mac-2 Binding Protein Glycosylation Isomer Combination Improve Detection of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Study. Gastro Hep Adv, 2026. 5(5): p. 100901.
  23. Yi, H., et al., Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies. Endocr Pract, 2025. 31(8): p. 995-1001.
Recommended Articles
Research Article
Anatomy of the Danger Zones: Relationship Between Nerve-Sparing Surgical Techniques and Chronic Postoperative Pain Following Laparoscopic Inguinal Hernia Repair.
...
Published: 21/11/2026
Research Article
Prenatal and Postnatal Risk Factors for Retinopathy of Prematurity: A Prospective Analysis of 250 Preterm Neonates
...
Published: 21/11/2026
Research Article
Anatomical Variations of the inferior Epigastric Vessels and their Association with Port site Complications Following Laparoscopic Abdominal Surgery: A Comparative Cross-Sectional Study
...
Published: 20/11/2026
Research Article
Histopathological and Biomarker-Based Assessment of Oral Potentially Malignant Disorders: Correlation with Dysplastic Changes and Disease Progression
...
Published: 20/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine